PubMed HealthSearch

PubMed · 2865873

Beta blockade and intermittent claudication.

Abstract

The aim of the present study was to evaluate whether beta blockade presents a risk of intermittent claudication and how it affects the walking capacity and lower limb haemodynamics in patients with intermittent claudication. The study was divided into six parts: A case-control study with 55 pairs, cases with hypertension and intermittent claudication and controls with hypertension only, matched for age, sex, place of residence, and time of examination, all without coronary heart disease, which is a known confounding factor. An open controlled study on the effect of withdrawal of beta blockade on walking capacity of 28 patients with intermittent claudication. A placebo-controlled double-blind crossover study on the effect of antihypertensive treatment on the walking capacity of 14 patients with intermittent claudication. Three placebo-controlled double-blind crossover studies on the effect of propranolol, metoprolol, pindolol, labetalol, and/or methyldopa on calf blood flow in 34 hypertensive subjects without peripheral arterial disease and in altogether 21 patients with intermittent claudication. Walking capacity was measured on a treadmill. Calf blood flow was measured with strain gauge plethysmography by the venous occlusion technique. The case-control comparison showed that beta blockers were used as often by patients with intermittent claudication as by controls. Walking capacity increased during the first month of the open controlled study irrespective of whether the beta blockade was withdrawn or continued. There was no difference in this respect between the various types of beta blockers. Antihypertensive treatment with metoprolol or methyldopa did not affect walking capacity. Resting calf blood flow was unaffected by propranolol or metoprolol, regardless of the presence or absence of peripheral arterial disease, as well as by pindolol, labetalol, or methyldopa in patients with intermittent claudication. During reactive hyperaemia, propranolol and metoprolol reduced flow in patients without peripheral arterial disease. Propranolol also reduced hyperaemic blood flow in the limb with less or no symptoms in patients with intermittent claudication. None of the active drugs decreased the hyperaemic flow consistently in the limb with the stronger symptoms. In a comparison of haemodynamic effects between the drugs, calf blood flow at rest was higher after pindolol than after propranolol and hyperaemic flow of the better limb was higher after pindolol than after propranolol and labetalol.(ABSTRACT TRUNCATED AT 400 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Lepäntalo. 1985. Beta blockade and intermittent claudication.. https://pubmed.ncbi.nlm.nih.gov/2865873/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Beta-adrenergic blockers as cardioprotective agents.

The evidence supporting and describing cardioprotective effects of beta-adrenergic blocker treatment is surveyed. Details of the many studies that individually and collectively document the ability of long-term and acute beta-blocker therapy to reduce overall mortality, sudden cardiovascular death, and nonfatal reinfarction in patients surviving or experiencing a myocardial infarction are described. A discussion of the mechanisms by which beta blockers probably and theoretically achieve these benefits includes the suggestion that they may reduce plaque rupture, thus indirectly inhibiting thrombosis. It is also suggested that, in the future, further cardioprotective benefits may accrue to the use of beta blockers in conjunction with thrombolysis and of beta blockers with a duration of action sustained throughout a full 24 hours.

Adrenergic beta-Antagonists

[Developments in the treatment of myocardial infarction in Switzerland 1986-1990: results of a population survey].

The Swiss cantons of Vaud and Fribourg participate in the international MONICA project (MONI-toring of trends and determinants in CArdiovascular disease). Within this context, drug therapies and procedures were recorded during two separate years (1986 and 1990) for all hospitalizations of men aged 25 to 64 with the diagnosis of myocardial infarction. The medical files were reviewed to classify this diagnosis as possible or definite on the basis of the symptoms, the ECG results and the enzymatic tests. The two study populations (n = 318 in 1986 and n = 332 in 1990) are comparable with respect to age, history of ischemic heart disease and initial care. In 1990, half of the patients arrived at hospital in less than 3 hours, the median time delay being 4 hours for those first attending a general practitioner and 2 hours for those transferred directly. The frequency of treatments between 1986 and 1990 is compared only for cases with a definite diagnosis of myocardial infarction (respectively n = 217 and n = 223). The proportion of patients given thrombolytic therapy rose from 9% to 44% (p < 0.005) and from 51% to 95% (p < 0.005) for those treated with antiplatelet drugs, whereas the proportion fell from 72% to 55% (p < 0.005) for calcium blockers and from 33% to 24% (p < 0.05) for inotropic drugs. The use of anticoagulants (in 98% of patients) and of beta blockers (in 57%) remained stable across time.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists